Hodges Capital Management Inc. purchased a new stake in G1 Therapeutics Inc (NASDAQ:GTHX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 14,709 shares of the company’s stock, valued at approximately $292,000. Hodges Capital Management Inc. owned approximately 0.05% of G1 Therapeutics as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in G1 Therapeutics in the second quarter valued at $34,093,000. Emerald Advisers Inc. PA lifted its position in G1 Therapeutics by 2.5% during the third quarter. Emerald Advisers Inc. PA now owns 728,433 shares of the company’s stock valued at $18,131,000 after buying an additional 17,977 shares during the period. Chartwell Investment Partners LLC lifted its position in G1 Therapeutics by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after buying an additional 4,388 shares during the period. Vanguard Group Inc. purchased a new position in G1 Therapeutics during the second quarter valued at $1,291,000. Finally, Goldman Sachs Group Inc. purchased a new position in G1 Therapeutics during the second quarter valued at $1,144,000. Institutional investors and hedge funds own 43.25% of the company’s stock.
G1 Therapeutics Inc (NASDAQ GTHX) opened at $19.38 on Friday. G1 Therapeutics Inc has a 52-week low of $12.04 and a 52-week high of $28.67.
Several brokerages have commented on GTHX. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. JPMorgan Chase & Co. raised their price objective on G1 Therapeutics to $30.00 in a research report on Monday, February 5th. BidaskClub lowered G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. BTIG Research began coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price objective for the company. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. G1 Therapeutics presently has a consensus rating of “Buy” and an average target price of $32.80.
In related news, Director Fredric N. Eshelman purchased 250,000 shares of the stock in a transaction dated Monday, November 13th. The stock was purchased at an average price of $19.73 per share, with a total value of $4,932,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $22.96, for a total value of $86,696.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 546,682 shares of company stock valued at $10,865,628.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.